Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Google Secures Pentagon AI Deal for Classified Projects 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
GAITHERSBURG, Md., April 20, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 4, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2017, recent business developments, revenue guidance for the second quarter of 2017, and revenue and net income guidance for full year 2017.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: Dial in number: (855) 766-6521 International dial in: (262) 912-6157 Conference ID: 29691796 |
| Live Webcast Information: |
| Visit http://edge.media-server.com/m/p/523ryq7t for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 [email protected]
